Your competitor isn’t “just innovating.” They’re extending. Here are 4 signals to watch.
In pharma, the most expensive word isn’t “patent.” It’s “extension.”
When a drug’s core protection is nearing its end, competitors don’t always wait for the clock …
Read the Patent Trail: 4 Signals Your Competitor Is Extending a Drug’s Life Read Post »
Biopharma bizdev teams don’t lose deals because they can’t sell. They lose deals because they’re pitching the wrong time horizon.
In licensing, partnering, and BD strategy, timing is everything—but most teams still treat packaging as an afterthought: a…
OpenAI’s “GPT for life sciences” is the kind of headline that makes everyone lean forward—then immediately ask the same question: Is this real progress, or just another layer of hype on top of drug development?
Here’s the uncomfortable truth: most AI a…
GPT-Rosalind: What OpenAI’s Life Sciences Model Actually Does to Drug Development Read Post »
Biosimilar timelines are won—or lost—before the public “launch window” ever appears.
Most teams treat patent expiry intelligence like a calendar: identify the date, map the landscape, then wait for the market to open. That approach is understandable—…
Drug patents in Europe: the clock starts ticking the moment you file—and it rarely ends cleanly.
If you’re building a pipeline, underwriting risk, or planning market entry in Europe, the biggest misconception is that “patent protection” is a single, fi…
European Drug Patents: Exactly How Long Protection Lasts — and Where It Breaks Down Read Post »
Drug discovery timelines are getting longer—not because science is standing still, but because the workflow is. From target identification to protocol design, from literature triage to experimental planning, teams are still spending too much time trans…
Slash drug discovery timelines with GPT-Rosalind Read Post »
The exclusivity cliff isn’t a cliff anymore—it’s a calendar. Here’s how commercial market access teams can monetize it before generics arrive.
If you work in commercial market access, you’ve felt it: the moment a brand’s “last day of exclusivity” stops…
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer advantage is supposed to be durable. File early, win the patent dance, secure exclusivity, and capture outsized returns before competition arrives. But in to…
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits Read Post »
Read the Clock Right: Mapping Regulatory Exclusivities for True Generic Entry Timing
Generic drug competition is often described as a race to the finish line. But in practice, it’s more like air-traffic control: multiple signals, overlapping rules, and…
Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…
Get new actionable insights and updates from BiotechBlog
